Financial Comparison: ALX Oncology (NASDAQ:ALXO) versus Medicus Pharma (NASDAQ:MDCX)

ALX Oncology (NASDAQ:ALXO) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Valuation & Earnings

This table compares ALX Oncology and Medicus Pharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69 million	($1.49)	-1.28
Medicus Pharma	N/A	N/A	-$35.46 million	($2.68)	-0.14

ALX Oncology is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

ALX Oncology has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Comparatively, Medicus Pharma has a beta of 0.12, suggesting that its share price is 88% less volatile than the S&P 500.

Profitability

This table compares ALX Oncology and Medicus Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Medicus Pharma	N/A	-3,137.84%	-311.33%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for ALX Oncology and Medicus Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1	0	5	0	2.67
Medicus Pharma	1	1	2	0	2.25

ALX Oncology currently has a consensus price target of $4.60, suggesting a potential upside of 142.11%. Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 2,274.67%. Given Medicus Pharma’s higher possible upside, analysts plainly believe Medicus Pharma is more favorable than ALX Oncology.

Insider and Institutional Ownership

98.0% of ALX Oncology shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by company insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

ALX Oncology beats Medicus Pharma on 8 of the 11 factors compared between the two stocks.

About ALX Oncology

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.